Jérémie Nsengimana

Functional characterization of the 9q34.13 locus identifies RAPGEF1 as modulating risk for melanoma and nevi via RAS activation

This study identifies RAPGEF1 as a gene modulating melanoma and nevi risk through RAS activation, using fine-mapping, expression data, and functional assays.

Functional characterization of a multi-cancer risk locus on chromosome band 2q33.1 near CASP8

The paper identifies rs3769823 as a functional variant near CASP8 influencing its expression in a cell-type specific manner and associated with multiple cancers.

Extracellular vesicles from a model of melanoma cancer-associated fibroblasts induce changes in brain microvascular cells consistent with pre-metastatic niche priming.

This study shows that melanoma cancer-associated fibroblast-derived extracellular vesicles alter the tumor microenvironment and pre-metastatic niche, promoting melanoma metastasis.

Glucocorticoids unleash immune-dependent melanoma control through inhibition of the GARP/TGF-β axis

This study shows glucocorticoids enhance anti-tumor immunity by inhibiting the GARP/TGF-β axis in melanoma, improving prognosis and response to immunotherapy.

Inherited duplications of PPP2R3B promote naevi and melanoma via a novel C21orf91-driven proliferative phenotype

This study identifies inherited PPP2R3B duplications as a melanoma predisposing factor, revealing a C21orf91-driven proliferative phenotype in melanocytes.

Tumour gene expression signature in primary melanoma predicts long-term outcomes: A prospective multicentre study

This paper develops a gene expression signature, Cam_121, to predict long-term outcomes in primary melanoma patients, showing improved accuracy compared to clinical and existing prognostic models.

A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination